Advertisements



Palmer: PRV-031 could be first ever disease modifying type 1 diabetes therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Valeritas V-Go demonstrates benefits compared to MDI therapy for type 2 diabetes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 2nd, 2018

6 simple, science-backed ways to get rid of belly fat

Shutterstock/ nd3000  Having lots of fat in the abdominal area is strongly linked to diseases like type 2 diabetes and heart disease. Excess sugar and carb consumptio.....»»

Category: topSource: businessinsiderApr 12th, 2018

Stem cell research is paying off for New York

Most of us, at least once in our lives, are faced with a loved one diagnosed with cancer, diabetes, heart disease, sickle cell or another disease for which there is no cure. Twenty years ago, a... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkOct 10th, 2018

Lexicon Likely Looking At Even More Competition In Type 1 Diabetes

Lexicon Likely Looking At Even More Competition In Type 1 Diabetes.....»»

Category: topSource: seekingalphaOct 5th, 2018

Eli Lilly"s Ultra Rapid Lispro Succeeds in Diabetes Studies

Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-infer.....»»

Category: dealsSource: nytOct 3rd, 2018

Novo Nordisk: Type 1 Diabetes Treatments To Boost Growth

Novo Nordisk: Type 1 Diabetes Treatments To Boost Growth.....»»

Category: topSource: seekingalphaOct 1st, 2018

Alnylam stock drops 2.6% premarket on preliminary results for rare disease therapy

Alnylam Pharmaceuticals Inc. shares dropped 2.6% in Thursday premarket trade after the company released early results from a phase 3 trial fo.....»»

Category: topSource: marketwatchSep 27th, 2018

Nationwide Children"s gene therapy spinoff acquired for $100M

Yet another gene therapy spinoff from Nationwide Children's Hospital has been acquired for $100 million. Celenex is developing a treatment for Batten Disease, a rare, fatal neurological condition that causes blindness and progressive loss of spee.....»»

Category: topSource: bizjournalsSep 21st, 2018

Many Americans With Diabetes Do Not Know It

Many Americans With Diabetes Do Not Know It It’s estimated more than 30% of American adults with diabetes don’t realize they are suffering from this potentially deadly disease. Data from the National Health.....»»

Category: topSource: livetradingnewsSep 20th, 2018

BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy

BioCryst Pharmaceuticals Inc. shares surged more than 6% premarket on the news that it has won a $35 million, five-year contract from the Centers for Disease Control and Prevention for up to 50,000 doses of its antiviral flu t.....»»

Category: topSource: marketwatchSep 6th, 2018

Novo Nordisk"s Ozempic Lowers Risk of Cardiovascular Events (revised)

Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population. Novo Nordisk A/S NVO announce.....»»

Category: worldSource: nytSep 4th, 2018

Pfizer stops developing therapy for the rare disease Duchenne muscular dystrophy

Pfizer Inc. is ending ongoing research for a Duchenne muscular dystrophy drug after finding that the evidence "did not support a significant treatment effect," the company said on Thursday. Shares slumped 0.5% premarket, while shares of DMD drugmaker S.....»»

Category: topSource: marketwatchAug 30th, 2018

Regenxbio expands pipeline with RGX-181 gene therapy for Batten disease

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 30th, 2018

Nemours finishes historic children"s diabetes research

As part of a research project conducted by four institutions across the nation, one Jacksonville hospital is taking part in the next big break in type 1 diabetes treatment. Researchers at Nemours Children's Specialty Care on the Southbank of the S.....»»

Category: topSource: bizjournalsAug 15th, 2018

Scientists have found a way to calculate your risk for deadly conditions like diabetes, breast cancer and heart disease

Flickr/Micah Baldwin A new genetic test which can test how likely a person is to contract serious conditions like heart disease and diabetes has been developed, according to a st.....»»

Category: topSource: businessinsiderAug 14th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on average

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 11th, 2018

Alnylam Makes History With Approval Of RNA Therapy

Biopharmaceutical company Alnylam Pharmaceuticals (NASDAQ: ALNY) made history this week by kickstarting the future of gene therapy and disease research. read more.....»»

Category: blogSource: benzingaAug 10th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on oaverage

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 10th, 2018

Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls

Avrobio Inc (NASDAQ: AVRO), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million shares in an IPO. Latest Ratings for AVRO Dat.....»»

Category: blogSource: benzingaJul 16th, 2018

Why Being Skinny Fat Could Be Just as Dangerous as Being Obese

The skinny fat body type has been linked to heart disease and dementia......»»

Category: topSource: newsweekJul 13th, 2018